Journal of Medicinal Chemistry · 2011 · 100 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyChemical Probe DiscoveryEnzyme InhibitionLigand BindingLigand-based DesignMolecular DockingStructure-activity Relationship AnalysisBiological Evaluation ReportCytotoxicity AssaysDocking-based Drug DesignLabelingMolecular Docking Of InhibitorsNeuroprotective MechanismsPhotoaffinity ProbesStructure-based Screening
The design, synthesis, docking, and biological evaluation of novel potent HDAC3 and HDAC8 isoxazole- and pyrazole-based diazide probes suitable for binding ensemble profiling with photoaffinity labeling (BEProFL) experiments in cells is described. Both the isoxazole- and pyrazole-based probes exhibit low nanomolar inhibitory activity against HDAC3 and HDAC8, respectively. The pyrazole-based probe 3f appears to be one of the most active HDAC8 inhibitors reported in the literature with an IC(50) of 17 nM. Our docking studies suggest that unlike the isoxazole-based ligands the pyrazole-based ligands are flexible enough to occupy the second binding site of HDAC8. Probes/inhibitors 2b, 3a, 3c, and 3f exerted the antiproliferative and neuroprotective activities at micromolar concentrations through inhibition of nuclear HDACs, indicating that they are cell permeable and the presence of an azide or a diazide group does not interfere with the neuroprotection properties, or enhance cellular cytotoxicity, or affect cell permeability.
23
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Bhupinder Mann, John R. Johnson, Martin H. Cohen et al. · The Oncologist · 2007 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Emma Hockly, Victoria M. Richon, Benjamin Woodman et al. · Proceedings of the National Academy of Sciences · 2003 · 841 citations · Full text